secondary endpoints from a trial of pembrolizumab plus chemotherapy for metastatic tnbc
Published 3 years ago • 26 plays • Length 5:34Download video MP4
Download video MP3
Similar videos
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
10:14
asco: pembrolizumab plus chemotherapy for advanced triple-negative breast cancer
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
4:38
alice: atezolizumab immunogenic chemotherapy in metastatic tnbc
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
1:06
dr. tolaney on pembrolizumab plus eribulin in tnbc
-
9:59
gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
-
2:00
pembrolizumab plus chemotherapy show efficacy for tnbc in keynote-355
-
28:25
metastatic triple-negative breast cancer ongoing trials
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
6:30
case study: treating metastatic triple-negative breast cancer
-
7:14
ascent: sacituzumab govitecan vs treatment of physician’s choice in patients with previously tre...
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer